Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 184

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

Open access
Blumenthal, Gideon M., Bunn, Paul A., Chaft, Jamie E., McCoach, Caroline E., Perez, Edith A., Scagliotti, Giorgio V., Carbone, David P., Aerts, Hugo J.W.L., Aisner, Dara L., Bergh, Jonas, Berry, Donald A., Jarkowski, Anthony, Botwood, Nicholas, Cross, Darren A.E., Diehn, Max, Drezner, Nicole L., Doebele, Robert C., Blakely, Collin M., Eberhardt, Wilfried E.E., Felip, Enriqueta, Gianni, Luca, Keller, Steven P., Leavey, Patrick J., Malik, Shakun, Pignatti, Francesco, Prowell, Tatiana M., Redman, Mary W., Rizvi, Naiyer A., Rosell, Rafael, Rusch, Valerie, de Ruysscher, Dirk, Schwartz, Lawrence H., Sridhara, Rajeshwari, Stahel, Rolf A., Swisher, Stephen, Taube, Janis M., Travis, William D., Keegan, Patricia, Wiens, Jacinta R., Wistuba, Ignacio I., Wynes, Murry W., Hirsch, Fred R., Kris, Mark G. · 2018 · Journal of Thoracic Oncology

Abstract

This Review Article provides a multi‐stakeholder view on the current status of neoadjuvant therapy in lung cancer. Given the success of oncogene‐targeted therapy and immunotherapy for patients with advanced lung cancer, there is a renewed interest in studying these agents in earlier disease settings with the opportunity to have an even greater impact on patient outcomes. There are unique opportunities and challenges with the neoadjuvant approach to drug development. To achieve more rapid knowledge turns, study designs, endpoints, and definitions of pathologic response should be standardized and harmonized. Continued dialogue with all stakeholders will be critical to design and test novel induction strategies, which could expedite drug development for patients with early lung cancer who are at high risk for metastatic recurrence.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2018.09.017

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 184

Metadata

Authors
Blumenthal, G. M., Bunn, P. A., Chaft, J. E., McCoach, C. E., Perez, E. A., Scagliotti, G. V., Carbone, D. P., Aerts, H. J. W. L., Aisner, D. L., Bergh, J., Berry, D. A., Jarkowski, A., Botwood, N., Cross, D. A. E., Diehn, M., Drezner, N. L., Doebele, R. C., Blakely, C. M., Eberhardt, W. E. E., Felip, E., Gianni, L., Keller, S. P., Leavey, P. J., Malik, S., Pignatti, F., Prowell, T. M., Redman, M. W., Rizvi, N. A., Rosell, R., Rusch, V., de Ruysscher, D., Schwartz, L. H., Sridhara, R., Stahel, R. A., Swisher, S., Taube, J. M., Travis, W. D., Keegan, P., Wiens, J. R., Wistuba, I. I., Wynes, M. W., Hirsch, F. R., & Kris, M. G.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2018-12
Volume
13
Issue
12
Pages
1818-1831
ISSN
1556-0864 (ISSN-L)
OpenAlex
W2892483359
Cited by
184
References
15
FWCI
13.70
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. https://app.cochat.ai/papers/10.1016/j.jtho.2018.09.017
The paper
Blumenthal, G. M., Bunn, P. A., Chaft, J. E., McCoach, C. E., Perez, E. A., Scagliotti, G. V., Carbone, D. P., Aerts, H. J. W. L., Aisner, D. L., Bergh, J., Berry, D. A., Jarkowski, A., Botwood, N., Cross, D. A. E., Diehn, M., Drezner, N. L., Doebele, R. C., Blakely, C. M., Eberhardt, W. E. E., . . . Kris, M. G. (2018). Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2018.09.017

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.